Cycrimine
Cycrimine (trade name Pagitane) is a central anticholinergic drug designed to reduce the levels of acetylcholine in the treatment of Parkinson's disease. Its mechanism of action is to bind to the muscarinic acetylcholine receptor M1.[1]
Clinical data | |
---|---|
License data |
|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.000.932 |
Chemical and physical data | |
Formula | C19H29NO |
Molar mass | 287.447 g·mol−1 |
3D model (JSmol) | |
| |
|
Synthesis
See also
References
- Usdin E, Efron DH, eds. (1979). Psychotropic Drugs and Related Compounds (2nd ed.). Washington, DC: Pergamon Press. p. 218. ISBN 978-0-08-025510-1. OCLC 715151908.
- Denton JJ, Schedl HP, Lawson VA, Neier WB (1950). "Antispasmodics. VII.1 Additional Morpholinyl and Piperidyl Tertiary Alcohols". Journal of the American Chemical Society. 72 (8): 3795–3796. doi:10.1021/ja01164a127.
External links
- Cycrimine at DrugLib.com
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.